Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference

Mar 11, 2011 08:19AM Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Failed Aflibercept Trial in 2nd-line Lung Cancer Doesn’t Change Our Thesis

Feb 17, 2011 04:28PM Needham & Company maintains a 'Buy' on Regeneron Pharma (REGN); Believe 2011 Will Build on Successes of 2010

Feb 14, 2011 07:59AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Angiogenesis Mtg Highlights Robust Full Dataset for Multiple VEGF Trap-Eye Trials

Jan 5, 2011 08:23AM Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Positioned for Transformational Year

Nov 12, 2010 08:12AM Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharma (REGN)

Aug 2, 2010 09:16AM Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharmaceuticals (REGN); Multiple Catalysts in 2H10 to Potentially Drive the Stock Valuation

Jul 16, 2010 08:49AM Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Investor Day Review – Have More Confidence in the Clinical Trial and Commercialization in Gout

May 3, 2010 07:45AM Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Preview Shows Progress in Both Late-Stage Programs

Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)